1)Marabelle A, et al : Association of tumor mutational burden with outcomes in patients with advanced solid tumors treated with pembrolizumab : prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21 : 1353-1365, 2020
2)Vanderwalde A, et al : Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med 7 : 746-756, 2018
3)Marabelle A, et al : Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer : results from the phase II KEYNOTE-158 study. J Clin Oncol 38 : 1-10, 2020
4)Makker V, et al : Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 386 : 437-448, 2022
5)Eskander RN, et al : Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med, 2023(in press)